Intra-Cellular Therapies (ITCI) extends gain after CAPLYTA approved by FDA for treatment of schizophrenia in adults, up 80%
Tweet Send to a Friend
Intra-Cellular Therapies (NASDAQ: ITCI) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
